Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Neuphoria Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurological and psychiatric disorders. With minimal revenue, exceptionally high gross margins (95.8%), and negative operating margins, the company operates in the pre-commercialization phase typical of drug development firms. The stock trades at 0.9x sales and 0.6x book value with significant recent underperformance (-49.9% over six months), reflecting either clinical setbacks, funding concerns, or broader biotech sector weakness.
As a clinical-stage company, Neuphoria currently generates minimal revenue primarily through research grants, government funding (NIH/NIMH grants), and potential collaboration agreements with larger pharmaceutical partners. The 95.8% gross margin suggests grant/collaboration revenue with minimal direct costs. The business model depends on advancing drug candidates through Phase I/II/III trials, achieving regulatory milestones, and ultimately either commercializing approved therapies or licensing/selling assets to larger pharma companies. Value creation hinges on clinical trial success rates, intellectual property protection around novel mechanisms of action, and ability to secure non-dilutive funding. The company's 9.04 current ratio and positive free cash flow ($0.1B) suggest adequate near-term liquidity to fund operations, though cash burn rate and runway to next financing are critical metrics.
Clinical trial data readouts - Phase I safety data, Phase II efficacy endpoints, patient enrollment milestones
FDA regulatory interactions - IND approvals, Fast Track/Breakthrough Therapy designations, meeting outcomes
Partnership announcements - licensing deals, co-development agreements with big pharma providing validation and non-dilutive funding
Cash runway updates - quarterly burn rate, financing announcements (equity raises, debt facilities, PIPE transactions)
Competitive landscape changes - rival programs' clinical failures/successes in same therapeutic areas
Sector-wide biotech sentiment - IPO market conditions, M&A activity, risk appetite for clinical-stage assets
Clinical trial failure risk - neurological/psychiatric indications historically have high Phase II/III failure rates (60-70%) due to complex endpoints, placebo effects, and heterogeneous patient populations
Regulatory pathway uncertainty - FDA requirements for CNS drugs increasingly stringent with demands for long-term safety data and real-world evidence
Reimbursement pressure - payers scrutinizing neuropsychiatric drug pricing, requiring robust health economics data for formulary access
Patent cliff exposure - if lead candidates rely on composition-of-matter patents nearing expiration, commercial runway may be limited
Large pharmaceutical companies (Eli Lilly, Johnson & Johnson, Biogen) with established neuroscience franchises, deeper pockets for clinical development, and commercial infrastructure
Competitive clinical programs targeting same mechanisms of action or indications could reach market first, establishing standard of care
Generic/biosimilar competition if approved therapies lack strong differentiation or patent protection
Dilution risk from future equity financings - with minimal revenue and negative operating margins, company will require additional capital raises to fund trials through commercialization
Cash runway risk - if clinical trials experience delays or require expansion, current cash may be insufficient, forcing financing at unfavorable terms
Negative ROE (-7.8%) and ROA (-1596.4%) reflect shareholder value destruction in pre-revenue phase, though typical for clinical-stage biotechs
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones rather than economic cycles. However, financing availability (equity raises, venture funding) correlates with risk appetite during economic expansions versus contractions. Recession periods typically see biotech IPO windows close and valuation multiples compress, making capital raises more dilutive.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (clinical-stage companies have 5-10+ year timelines to profitability). Higher rates also increase opportunity cost of capital, making speculative biotech investments less attractive versus fixed income. Additionally, rising rates can tighten venture capital and growth equity funding availability. The company's zero debt means no direct financing cost impact, but equity financing becomes more expensive in high-rate environments.
Minimal direct credit exposure given zero debt and strong 9.04 current ratio. However, broader credit market conditions affect ability to secure venture debt facilities or convertible notes as non-dilutive financing alternatives. Tight credit conditions can force reliance on dilutive equity raises.
growth - Attracts speculative growth investors, biotech-focused hedge funds, and venture capital seeking asymmetric risk/reward from binary clinical outcomes. Not suitable for value or income investors given negative earnings, no dividends, and high uncertainty. Recent -49.9% six-month decline suggests momentum investors have exited. Typical holders include specialized healthcare funds, crossover investors (late-stage VC/early public equity), and retail investors with high risk tolerance.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial data, FDA decisions). Small market cap and likely low float amplify price swings. Recent performance shows significant drawdowns (-49.9% six months, -23.0% one year), consistent with high-beta biotech profile. Expect 50-100%+ single-day moves on material clinical or regulatory news.
